Skip to main content

Table 1 Patient demographics and baseline characteristics (randomized population)

From: A 16-week study to compare the effect of vildagliptin versus gliclazide on postprandial lipoprotein concentrations and oxidative stress in patients with type 2 diabetes inadequately controlled with metformin monotherapy

Demographic

Gliclazide (n = 18)

Vildagliptin (n = 18)

Age (years)

55.4 ± 11.3

59.4 ± 8.9

Sex (number of men)

6

12

BMI (kg/m2)

30.68 ± 4.3

29.35 ± 4.3

Duration of diabetes (years)

4.4 ± 2.6

4.3 ± 2.7

Duration of previous metformin treatment (months)

All patients were on metformin treatment for ≥3 months on stable dose (≥1000 mg/daily)

Metformin daily dose (mg)

1457 ± 373

1584 ± 528

Gliclazide daily dose (mg)

86,80 ± 28,10

-

  1. Data are means ± SD unless otherwise indicated